Total Valuation
Protara Therapeutics has a market cap or net worth of €131.54M. The enterprise value is €93.30M.
Market Cap€131.54M
Enterprise Value€93.30M
Share Statistics
Protara Therapeutics has 59,095,490 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding59,095,490
Owned by Insiders2.84%
Owned by Institutions<0.01%
Financial Efficiency
Protara Therapeutics’s return on equity (ROE) is -0.29 and return on invested capital (ROIC) is -32.31%.
Return on Equity (ROE)-0.29
Return on Assets (ROA)-0.27
Return on Invested Capital (ROIC)-32.31%
Return on Capital Employed (ROCE)-0.33
Revenue Per Employee0.00
Profits Per Employee-1.25M
Employee Count46
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Protara Therapeutics is ―. Protara Therapeutics’s PEG ratio is 0.10.
PE Ratio―
PS Ratio0.00
PB Ratio1.16
Price to FCF-4.04
Price to Operating Cash Flow-2.25
PEG Ratio0.10
Income Statement
In the last 12 months, Protara Therapeutics had revenue of 0.00 and earned -57.44M in profits. Earnings per share was -1.34.
Revenue0.00
Gross Profit-362.00K
Operating Income-64.55M
Pretax Income-57.44M
Net Income-57.44M
EBITDA-57.08M
Earnings Per Share (EPS)-1.34
Cash Flow
In the last 12 months, operating cash flow was -66.13M and capital expenditures -360.00K, giving a free cash flow of -66.49M billion.
Operating Cash Flow-66.13M
Free Cash Flow-66.49M
Free Cash Flow per Share-1.13
Dividends & Yields
Protara Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.89
52-Week Price Change-48.90%
50-Day Moving Average2.85
200-Day Moving Average3.86
Relative Strength Index (RSI)41.31
Average Volume (3m)187.00
Important Dates
Protara Therapeutics upcoming earnings date is Oct 29, 2026, Before Open (Confirmed).
Last Earnings DateAug 11, 2026
Next Earnings DateOct 29, 2026
Ex-Dividend Date―
Financial Position
Protara Therapeutics as a current ratio of 14.58, with Debt / Equity ratio of 1.70%
Current Ratio14.58
Quick Ratio14.58
Debt to Market Cap0.00
Net Debt to EBITDA0.81
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Protara Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Protara Therapeutics EV to EBITDA ratio is -3.19, with an EV/FCF ratio of -3.22.
EV to Sales0.00
EV to EBITDA-3.19
EV to Free Cash Flow-3.22
EV to Operating Cash Flow-3.23
Balance Sheet
Protara Therapeutics has €17.08M in cash and marketable securities with €2.75M in debt, giving a net cash position of €14.33M billion.
Cash & Marketable Securities€17.08M
Total Debt€2.75M
Net Cash€14.33M
Net Cash Per Share€0.24
Tangible Book Value Per Share€4.52
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Protara Therapeutics is €21.37, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target€21.37
Price Target Upside563.71% Upside
Analyst ConsensusStrong Buy
Analyst Count3
Revenue Growth Forecast―
EPS Growth Forecast22.63%